Aldeyra Therapeutics Inc
NASDAQ:ALDX
Intrinsic Value
Aldeyra Therapeutics, Inc. operates as a biotechnology company. [ Read More ]
The intrinsic value of one ALDX stock under the Base Case scenario is 0.92 USD. Compared to the current market price of 3.97 USD, Aldeyra Therapeutics Inc is Overvalued by 77%.
Valuation Backtest
Aldeyra Therapeutics Inc
Run backtest to discover the historical profit from buying and selling ALDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Aldeyra Therapeutics Inc
Current Assets | 147.8m |
Cash & Short-Term Investments | 142.8m |
Other Current Assets | 5m |
Non-Current Assets | 516.6k |
PP&E | 516.6k |
Current Liabilities | 22.3m |
Accounts Payable | 1.3m |
Accrued Liabilities | 5.8m |
Other Current Liabilities | 15.1m |
Non-Current Liabilities | 6.3m |
Other Non-Current Liabilities | 6.3m |
Earnings Waterfall
Aldeyra Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-42.8m
USD
|
Operating Income
|
-42.8m
USD
|
Other Expenses
|
5.3m
USD
|
Net Income
|
-37.5m
USD
|
Free Cash Flow Analysis
Aldeyra Therapeutics Inc
What is Free Cash Flow?
ALDX Profitability Score
Profitability Due Diligence
Aldeyra Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Aldeyra Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ALDX Solvency Score
Solvency Due Diligence
Aldeyra Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Aldeyra Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALDX Price Targets Summary
Aldeyra Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ALDX is 9.44 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.
Ownership
ALDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ALDX Price
Aldeyra Therapeutics Inc
Average Annual Return | 3.69% |
Standard Deviation of Annual Returns | 43.75% |
Max Drawdown | -90% |
Market Capitalization | 235m USD |
Shares Outstanding | 58 895 800 |
Percentage of Shares Shorted | 4.42% |
ALDX News
Last Important Events
Aldeyra Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Aldeyra Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aldeyra Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Lexington, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2014-05-02. The firm's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). The company has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The firm's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.
Contact
IPO
Employees
Officers
The intrinsic value of one ALDX stock under the Base Case scenario is 0.92 USD.
Compared to the current market price of 3.97 USD, Aldeyra Therapeutics Inc is Overvalued by 77%.